FGF21 Recombinant Rabbit mAb (S-2567-21)

Fibroblast growth factor 21 (FGF21) is a 181-amino-acid, liver-derived atypical member of the FGF family that functions as a fasting-induced hormone—binding β-Klotho–FGFR1c complexes in adipose tissue and brain—to orchestrate systemic glucose, lipid and energy homeostasis by promoting insulin sensitivity, enhancing white-fat browning and thermogenesis, suppressing hepatic gluconeogenesis and lipogenesis, and centrally modulating appetite and circadian behavior; its circulating levels surge in response to nutrient deprivation, protein restriction, high-sucrose or high-fat diets, cold exposure, mitochondrial stress and alcoholic or non-alcoholic liver injury, while pharmacologic administration of engineered FGF21 analogs has shown potent, dose-dependent reductions in body weight, plasma triglycerides, LDL-cholesterol and fasting glucose in obese, diabetic and NASH patients, making FGF21 a promising therapeutic target for metabolic disease.